In this randomized , double-blind , @-period , @-treatment , placebo - and active-controlled , multicenter , crossover study , @ ascending single doses of a proprietary glycopyrronium ( GP ) MDI were evaluated compared with Placebo MDI and open-label tiotropium ( TIO ) in study patients with COPD .